Teva Pharmaceutical Industries (NYSE:TEVA) received a $12.00 price objective from stock analysts at Oppenheimer in a research note issued to investors on Wednesday, TipRanks reports. The firm currently has a “buy” rating on the stock. Oppenheimer’s target price points to a potential upside of 41.69% from the stock’s previous close.
A number of other equities analysts also recently weighed in on TEVA. ValuEngine downgraded Teva Pharmaceutical Industries from a “sell” rating to a “strong sell” rating in a research note on Monday, March 25th. Zacks Investment Research upgraded Teva Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a research note on Wednesday, March 20th. SunTrust Banks began coverage on Teva Pharmaceutical Industries in a research note on Tuesday, March 19th. They issued a “hold” rating and a $17.00 target price on the stock. Maxim Group restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, February 14th. Finally, Credit Suisse Group lowered their price target on shares of Teva Pharmaceutical Industries from $26.00 to $20.00 and set a “neutral” rating on the stock in a report on Thursday, February 14th. Five research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries currently has an average rating of “Hold” and a consensus price target of $17.05.
Shares of NYSE TEVA opened at $8.47 on Wednesday. Teva Pharmaceutical Industries has a twelve month low of $8.25 and a twelve month high of $25.96. The company has a market capitalization of $8.86 billion, a PE ratio of 3.02, a price-to-earnings-growth ratio of 1.05 and a beta of 1.64. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.66.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 16.84% and a negative net margin of 18.66%. The firm had revenue of $4.30 billion for the quarter, compared to the consensus estimate of $4.38 billion. During the same quarter in the previous year, the business earned $0.94 EPS. The company’s revenue was down 15.2% compared to the same quarter last year. On average, analysts forecast that Teva Pharmaceutical Industries will post 2.26 EPS for the current fiscal year.
In other Teva Pharmaceutical Industries news, Director Sol J. Barer bought 111,000 shares of the stock in a transaction on Monday, June 3rd. The shares were acquired at an average price of $8.98 per share, with a total value of $996,780.00. Following the acquisition, the director now directly owns 115,942 shares of the company’s stock, valued at approximately $1,041,159.16. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Notaristefani Carlo De sold 16,070 shares of the business’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $11.42, for a total transaction of $183,519.40. Following the sale, the vice president now directly owns 49,659 shares in the company, valued at approximately $567,105.78. The disclosure for this sale can be found here. Insiders have sold a total of 18,860 shares of company stock worth $226,854 in the last three months. Insiders own 0.49% of the company’s stock.
A number of hedge funds have recently modified their holdings of TEVA. Northwestern Mutual Wealth Management Co. grew its position in Teva Pharmaceutical Industries by 4.0% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 19,861 shares of the company’s stock worth $311,000 after acquiring an additional 767 shares in the last quarter. ARK Investment Management LLC boosted its position in Teva Pharmaceutical Industries by 3.6% during the first quarter. ARK Investment Management LLC now owns 24,462 shares of the company’s stock valued at $384,000 after buying an additional 856 shares during the period. Hancock Whitney Corp boosted its position in Teva Pharmaceutical Industries by 7.8% during the fourth quarter. Hancock Whitney Corp now owns 12,056 shares of the company’s stock valued at $186,000 after buying an additional 868 shares during the period. Lindbrook Capital LLC boosted its position in Teva Pharmaceutical Industries by 61.2% during the first quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock valued at $39,000 after buying an additional 945 shares during the period. Finally, Cigna Investments Inc. New boosted its position in Teva Pharmaceutical Industries by 5.9% during the fourth quarter. Cigna Investments Inc. New now owns 17,342 shares of the company’s stock valued at $267,000 after buying an additional 959 shares during the period. 65.10% of the stock is currently owned by institutional investors and hedge funds.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Read More: Range Trading
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.